What to look forward to in breast cancer at ASCO 2023
Hope Rugo, MD, FASCO, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, talks on what to look out for at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023, including a detailed safety analysis of capivasertib in the Phase III CAPItello-291 (NCT04305496) trial, which assessed capivasertib in addition to fulvestrant in locally advanced or metastatic HR-positive, HER2-negative breast cancer. Based on the progression-free survival (PFS) results and trend in overall-survival (OS) of CAPItello-291, capivasertib will likely be approved in the US. Prof. Rugo additionally highlights the Phase III NATALEE (NCT03701334) trial evaluating efficacy and safety of 3 years of ribociclib with endocrine therapy versus placebo with endocrine therapy as adjuvant treatment in patients with HR-positive, HER2-negative early breast cancer. This interview took place at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
-
Category
No comments found